A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors

por Deutsch, Eric, Moyal, Elizabeth Cohen-Jonathan, Gregorc, Vanesa, Zucali, Paolo Andrea, Menard, Jean, Soria, Jean-Charles, Kloos, Ioana, Hsu, Jeff, Luan, Ying, Liu, Emily, Vezan, Remus, Graef, Thorsten, Rivera, Sofia
Publicado 2016

Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study

por Ribrag, Vincent, Kim, Won Seog, Bouabdallah, Reda, Lim, Soon Thye, Coiffier, Bertrand, Illes, Arpad, Lemieux, Bernard, Dyer, Martin J. S., Offner, Fritz, Felloussi, Zakia, Kloos, Ioana, Luan, Ying, Vezan, Remus, Graef, Thorsten, Morschhauser, Franck
Publicado 2017

Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia

por Wayne, Alan S., Huynh, Van, Hijiya, Nobuko, Rouce, Rayne H., Brown, Patrick A., Krueger, Joerg, Kitko, Carrie L., Dela Ziga, Edward, Hermiston, Michelle L., Richards, Michael K., Baruchel, Andre, Schuberth, Petra C., Rossi, John, Zhou, Lang, Goyal, Lovely, Jain, Rajul, Vezan, Remus, Masouleh, Behzad Kharabi, Lee, Daniel W.
Publicado 2022

Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies

por Ghobadi, Armin, Landmann, Jack H., Carter, Alun, Cooper, Matthew L., Selli, Mehmet Emrah, Chang, Jufang, Baker, Matthew, Miller, Christopher A., Ferraro, Francesca, Chen, David Y., Smith, Amanda M., LaValle, Taylor A., Duncavage, Eric J., Chou, Justin, Tam, Victor, Benoun, Joseph M., Nater, Jenny, Scholler, Nathalie, Milletti, Francesca, Vezan, Remus, Bot, Adrian, Rossi, John M., Singh, Nathan
Publicado 2022